Ustekinumab-induced sarcoidosis in a patient with psoriatic arthritis.
Ustekinumab-induced sarcoidosis in a patient with psoriatic arthritis.
Curr Drug Saf. 2020 Mar 16;:
Authors: Kobak S, Semiz H
Abstract
Psoriatic arthritis(PsA) is a chronic inflammatory disease which may affect many different joints. Sarcoidosis is a Th-1 cell related chronic granulomatous disease characterized by non-caseating granuloma formation. The coexistence of both diseases is a rare entity. In addition to conventional DMARDs, biological agents are also used in the treatment of PsA. One of these drugs is ustekinumab, an IL12 / 23 inhibitor that control both skin lesions and locomotor system findings. In this paper, we report the development of sarcoidosis in a 52 years old female patient treated with ustekinumab for PsA.
PMID: 32178618 [PubMed - as supplied by publisher]
Source: Current Drug Safety - Category: Drugs & Pharmacology Authors: Kobak S, Semiz H Tags: Curr Drug Saf Source Type: research
More News: Arthritis | Drugs & Pharmacology | Psoriatic Arthritis | Rheumatology | Sarcoidosis | Skin | Stelara